secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shockwave Medical, Inc. (—)
CIK:        0001642545
Form:       8-K
Filed at:   2023-04-11T23:59:59+00:00
Accession:  0001642545-23-000012
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shockwave Medical completes acquisition of Neovasc for $27.25/share cash plus up to $12.00 CVR
--------------------------------------------------------------------------------

- Total per-share consideration of $27.25 cash plus up to $12.00 CVR contingent on FDA approval of Neovasc Reducer.
- Reducer targets refractory angina; granted FDA Breakthrough Device designation; COSIRA-II study ongoing to support approval.
- Neovasc shares to be delisted from TSX and Nasdaq; Neovasc becomes wholly owned subsidiary of Shockwave.
- Consideration paid via Computershare; Israeli tax certification required for certain shareholders to avoid withholding.
- Deal valued at implied ~$39.25 per share if CVR milestones met; acquisition funded with cash on hand.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642545/000164254523000012/0001642545-23-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642545/000164254523000012/gnw-20230411.htm
  HTML page:      https://secwatch.observer/filing/0001642545-23-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer